#Sickle_Cell

Thiard News@F4F

@newsen.bsky.social

3 months ago

New Study Shows Novel Transdermal Curcumin Significantly Benefits Cardiac Function in Sickle Cell Disease A groundbreaking study from Vascarta Inc. shows that VAS-101, a transdermal curcumin, improves cardiac mitochondrial function in sickle cell disease, potentially changing treatment paradigms.

New Study Shows Novel Transdermal Curcumin Significantly Benefits Cardiac Function in Sickle Cell Disease #United_States #Sickle_Cell #VAS-101 #Summit #transdermal_curcumin

Thiard News@F4F

@newsen.bsky.social

5 months ago

Kenya, Uganda, and Côte d'Ivoire Join Forces for Sickle Cell Care Initiatives Kenya, Uganda, and Côte d'Ivoire are partnering with Terumo Blood and Cell Technologies to advance sickle cell disease treatment and care in their countries.

Kenya, Uganda, and Côte d'Ivoire Join Forces for Sickle Cell Care Initiatives #Lakewood #Kenya #Sickle_Cell #Terumo_Blood #JCRC

Thiard News@F4F

@newsen.bsky.social

6 months ago

CorrectSequence Therapeutics Reports Promising Results for Sickle Cell Disease Treatment with CS-101 A groundbreaking treatment for sickle cell disease, CS-101 from CorrectSequence Therapeutics, achieves significant success in a clinical trial involving a young patient, presenting a potential breakthrough.

CorrectSequence Therapeutics Reports Promising Results for Sickle Cell Disease Treatment with CS-101 #China #Shanghai #Sickle_Cell #CorrectSequence #CS-101

Thiard News@F4F

@newsen.bsky.social

6 months ago

Breakthrough in Sickle Cell Disease Treatment Using CS-101 by CorrectSequence Therapeutics CorrectSequence Therapeutics has achieved a significant milestone in sickle cell disease treatment with CS-101, demonstrating promising results in the first patient.

Breakthrough in Sickle Cell Disease Treatment Using CS-101 by CorrectSequence Therapeutics #China #Shanghai #Sickle_Cell #CorrectSequence #CS-101

Thiard News@F4F

@newsen.bsky.social

6 months ago

CorrectSequence Therapeutics Breakthrough in Sickle Cell Therapy with CS-101 Gene Editing CorrectSequence Therapeutics has reported transformative results from its CS-101 gene editing therapy for sickle cell disease, marking a significant advancement in treatment.

CorrectSequence Therapeutics Breakthrough in Sickle Cell Therapy with CS-101 Gene Editing #China #Shanghai #Sickle_Cell #CorrectSequence #CS-101

Thiard News@F4F

@newsen.bsky.social

8 months ago

Cellarity Launches Phase 1 Study for Novel Sickle Cell Treatment CLY-124 Cellarity has initiated a Phase 1 clinical trial for CLY-124, an innovative oral medication aimed at treating sickle cell disease with a unique Globin-Switching mechanism.

Cellarity Launches Phase 1 Study for Novel Sickle Cell Treatment CLY-124 #United_States #Somerville #Sickle_Cell #Cellarity #CLY-124

Thiard News@F4F

@newsen.bsky.social

9 months ago

Seventh Annual Shine the Light on Sickle Cell Campaign Promotes Awareness and Advocacy in Northeast U.S. The upcoming Shine the Light on Sickle Cell campaign unites 47 organizations to raise awareness for Sickle Cell Disease and advocate for better care and a universal cure.

Seventh Annual Shine the Light on Sickle Cell Campaign Promotes Awareness and Advocacy in Northeast U.S. #United_States #Philadelphia #Sickle_Cell #Health_Advocacy #Awareness_Campaign

Thiard News@F4F

@newsen.bsky.social

10 months ago

In Tribute to Phil Robinson: A Legacy of Vision and Resilience in Entertainment and Sports Phil Robinson, a cultural icon and business mastermind, left us at 58, inspiring many through his spirit and dedication to sickle cell advocacy.

In Tribute to Phil Robinson: A Legacy of Vision and Resilience in Entertainment and Sports #USA #Los_Angeles #Sickle_Cell #Legacy #Phil_Robinson

Thiard News@F4F

@newsen.bsky.social

1 year ago

Zynext Ventures Invests in Illexcor Therapeutics to Innovate Sickle Cell Disease Treatments Zynext Ventures has announced a significant investment in Illexcor Therapeutics to advance innovative oral therapies for sickle cell disease, highlighting their commitment to healthcare advancements.

Zynext Ventures Invests in Illexcor Therapeutics to Innovate Sickle Cell Disease Treatments #USA #Sickle_Cell #Zynext_Ventures #Illexcor #Pennington

Thiard News@F4F

@newsen.bsky.social

1 year ago

Breakthrough Transdermal Drug Candidate VAS-101 Offers Hope for Sickle Cell Patients Vascarta is set to initiate clinical trials for VAS-101, a transdermal treatment for sickle cell disease, which shows promise in alleviating pain and inflammation.

Breakthrough Transdermal Drug Candidate VAS-101 Offers Hope for Sickle Cell Patients #USA #Sickle_Cell #Vascarta #VAS-101 #Summit

Thiard News@F4F

@newsen.bsky.social

1 year ago

Partnering for Change: Combatting Sickle Cell Disease in Sub-Saharan Africa A groundbreaking initiative by Texas Children's Global HOPE, Baylor College of Medicine, and the Bristol Myers Squibb Foundation aims to fight sickle cell disease in Sub-Saharan Africa, enhancing children's health and well-being.

Partnering for Change: Combatting Sickle Cell Disease in Sub-Saharan Africa #United_States #Houston #Texas_Children's #Sickle_Cell #Baylor_College

Thiard News@F4F

@newsen.bsky.social

1 year ago

Revolutionary Curcumin Gel from Vascarta Could Transform Treatment for Sickle Cell Disease Vascarta Inc. presents promising new research at the American Society of Hematology Conference, highlighting a curcumin gel's potential to benefit sickle cell disease patients.

Revolutionary Curcumin Gel from Vascarta Could Transform Treatment for Sickle Cell Disease #USA #San_Diego #Sickle_Cell #Vascarta #Curcumin

Thiard News@F4F

@newsen.bsky.social

1 year ago

Novo Nordisk Unveils Breakthrough Data for Rare Blood Disorders at ASH 2024 Novo Nordisk announces exciting findings on innovative therapies for sickle cell disease and hemophilia at the upcoming ASH 2024 conference in San Diego.

Novo Nordisk Unveils Breakthrough Data for Rare Blood Disorders at ASH 2024 #USA #San_Diego #Novo_Nordisk #Sickle_Cell #Hemophilia